mTOR: Role in cancer, metastasis and drug resistance

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735

mTOR Signaling in Growth, Metabolism, and Disease

Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555

Epithelial–mesenchymal transitions in tumour progression

Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

Rho GTPases and the Actin Cytoskeleton

Hall, A. (1998) · Science · doi:10.1126/science.279.5350.509 · Cited by 6,138

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807

TOR signaling in growth and metabolism

Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Targeting PI3K/Akt signal transduction for cancer therapy

He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 2,045

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 810

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Yu, L., Wei, J., & Liu, P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 818

The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: an updated review

Rascio, F., Spadaccino, F., Rocchetti, M. T., Castellano, G., Stallone, G., Netti, G. S., & Ranieri, E. (2021) · Cancers · doi:10.3390/cancers13163949 · Cited by 497

Metabolism of Amino Acids in Cancer

Wei, Z. C., Liu, X., Cheng, C., Yu, W., & Yi, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.603837 · Cited by 456

Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells

Sun, Y., Berleth, N., Wu, W., Schlütermann, D., Deitersen, J., Stuhldreier, F., Berning, L., Friedrich, A., Akgün, S., Mendiburo, M. J., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04306-2 · Cited by 308

MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway

Lou, G., Chen, L., Xia, C., Wang, W., Qi, J., Li, A., Zhao, L., Chen, Z., Zheng, M., & Liu, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1512-5 · Cited by 296

The Role of mTOR Signaling as a Therapeutic Target in Cancer

Popova, N. V., & Jücker, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041743 · Cited by 273

Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products

Iksen, I., Pothongsrisit, S., & Pongrakhananon, V. (2021) · Molecules · doi:10.3390/molecules26134100 · Cited by 234

Targeting mTOR and Metabolism in Cancer: Lessons and Innovations

Magaway, C., Kim, E., & Jacinto, E. (2019) · Cells · doi:10.3390/cells8121584 · Cited by 231

Crosstalk between Sertoli and Germ Cells in Male Fertility

Wu, S., Yan, M., Ge, R., & Cheng, C. Y. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.09.006 · Cited by 168

Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer

Ou, X., Tan, Y., Xie, J., Yuan, J., Deng, X., Shao, R., Song, C., Cao, X., Xie, X., He, R., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101063 · Cited by 156

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells

Kurimchak, A. M., Herrera-Montávez, C., Montserrat-Sangrà, S., Araiza-Olivera, D., Hu, J., Neumann-Domer, R., Kuruvilla, M., Bellacosa, A., Testa, J. R., Jin, J., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2707 · Cited by 136

The significant role of amino acid metabolic reprogramming in cancer

Liu, X., Ren, B., Ren, J., Gu, M., You, L., & Zhao, Y.-P. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01760-1 · Cited by 147

Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121

Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer

Ashrafizadeh, M., Bakhoda, M. R., Bahmanpour, Z., Ilkhani, K., Zarrabi, A., Makvandi, P., Khan, H. Z., Mazaheri, S., Darvish, M., & Mirzaei, H. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00829 · Cited by 114

CCL18 in the Progression of Cancer

Korbecki, J., Olbromski, M., & Dzięgiel, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217955 · Cited by 110

Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives

Mortezaee, K., & Najafi, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103180 · Cited by 107

Curcumin downregulates the PI3K–AKT–mTOR pathway and inhibits growth and progression in head and neck cancer cells

Borges, G. Á., Elias, S. T., Amorim, B. R., de Lima, C. L., Coletta, R. D., CASTILHO, R. M., SQUARIZE, C. H., & Guerra, E. N. S. (2020) · Phytotherapy Research · doi:10.1002/ptr.6780 · Cited by 100

Nanomedicine Strategies in Conquering and Utilizing the Cancer Hypoxia Environment

Pan, Y., Liu, L., Mou, X., & Cai, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c07763 · Cited by 98

Glutamine addiction in tumor cell: oncogene regulation and clinical treatment

Li, X., Peng, X., Li, Y., Wei, S., He, G., Liu, J., Li, X., Yang, S., Dai, L., Lin, W., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01449-x · Cited by 103

Development and Validation of a Robust Ferroptosis-Related Prognostic Signature in Lung Adenocarcinoma

Zhang, A., Yang, J., Ma, C., Li, F., & Luo, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.616271 · Cited by 93

Body fatness associations with cancer: evidence from recent epidemiological studies and future directions

Larsson, S. C., Spyrou, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155326 · Cited by 89

Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action

Chen, J., Wu, S., Shi, Z.-M., & Hu, B. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00719-7 · Cited by 93

Hepatocellular carcinoma recurrence: Predictors and management

Abdelhamed, W., & El‐Kassas, M. (2023) · Liver Research · doi:10.1016/j.livres.2023.11.004 · Cited by 101

Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer

Evangelisti, C., Chiarini, F., Paganelli, F., Marmiroli, S., & Martelli, A. M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118635 · Cited by 83

Dual relationship between long non-coding RNAs and STAT3 signaling in different cancers: New insight to proliferation and metastasis

Ashrafizadeh, M., Gholami, M. H., Mirzaei, S., Zabolian, A., Haddadi, A., Farahani, M. V., Kashani, S. H., Hushmandi, K., Najafi, M., Zarrabi, A., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.119006 · Cited by 78

Emerging Roles of Liquid–Liquid Phase Separation in Cancer: From Protein Aggregation to Immune-Associated Signaling

Lu, J., Qian, J., Xu, Z., Yin, S., Zhou, L., Zheng, S., & Zhang, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.631486 · Cited by 77

Targeting lactate metabolism for cancer immunotherapy - a matter of precision

Heuser-Loy, C., Renner, K., Kreutz, M. P., & Gattinoni, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.001 · Cited by 77

Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents

Occhiuzzi, M. A., Lico, G., Ioele, G., Luca, M. D., Garofalo, A., & Grande, F. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114971 · Cited by 75

Annexin A2 : The diversity of pathological effects in tumorigenesis and immune response

Huang, Y., Jia, M., Yang, X., Han, H., Hou, G., Bi, L., Yang, Y., Zhang, R., Zhao, X., Peng, C., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34048 · Cited by 75

Aging conundrum: A perspective for ovarian aging

Wu, J., Liu, Y., Song, Y., Wang, L., Ai, J., & Li, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.952471 · Cited by 73

The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe?

Xu, J., Li, Y., Tang, Y., Xu, Z., Xu, H.-D., Cheng, X., & Qin, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621428 · Cited by 70

Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy

Cuomo, F., Altucci, L., & Cobellis, G. (2019) · Cancers · doi:10.3390/cancers11101465 · Cited by 64

ZDHHC22-mediated mTOR palmitoylation restrains breast cancer growth and endocrine therapy resistance

Huang, J., Li, J., Tang, J., Wu, Y., Yi, Z., Wang, Y., Li, Y., Tan, Y., Wu, Y., Ren, G., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70544 · Cited by 63

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

Tufail, M., Hu, J.-J., Liang, J., He, C., Wan, W., Huang, Y., Jiang, C., Wu, H., & Li, N. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04841-w · Cited by 65

PI3K-AKT/mTOR Signaling in Psychiatric Disorders: A Valuable Target to Stimulate or Suppress?

Chen, Y., Guan, W., Wang, M., & Lin, X. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae010 · Cited by 64

p62-Nrf2-p62 Mitophagy Regulatory Loop as a Target for Preventive Therapy of Neurodegenerative Diseases

Gureev, A. P., Sadovnikova, I. S., Starkov, N. N., Starkov, A. A., & Popov, V. N. (2020) · Brain Sciences · doi:10.3390/brainsci10110847 · Cited by 63

Antioxidative Stress: Inhibiting Reactive Oxygen Species Production as a Cause of Radioresistance and Chemoresistance

Chen, Y., Li, Y., Huang, L., Du, Y., Gan, F., Li, Y., & Yao, Y. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6620306 · Cited by 59

GALNT14 Regulates Ferroptosis and Apoptosis of Ovarian Cancer Through the EGFR/mTOR Pathway

Li, H.-W., Liu, M., Jiang, X., Song, T., Feng, S., Wu, J., Deng, P., & Wang, X. (2021) · Future Oncology · doi:10.2217/fon-2021-0883 · Cited by 57

Targeting mTOR for Anti-Aging and Anti-Cancer Therapy

Fu, W., & Wu, G. (2023) · Molecules · doi:10.3390/molecules28073157 · Cited by 62

Lactobacillus spp. create a protective micro-ecological environment through regulating the core fucosylation of vaginal epithelial cells against cervical cancer

Fan, Q., Wu, Y., Li, M., An, F., Yao, L., Wang, M., Wang, X., Yuan, J., Jiang, K., Li, M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04388-y · Cited by 58

To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway

Zhong, J., Ding, S., Zhang, X., Di, W., Wang, X., Zhang, H., Chen, Y., Zhang, Y., & Hu, Y. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2802037 · Cited by 61

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system

Zhao, B., Fu, Y., Cui, S., Chen, X., Liu, S., & Luo, L. F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1333662 · Cited by 53

mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2′,4′-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications

Lawal, B., Lee, C., Mokgautsi, N., Sumitra, M. R., Khedkar, H., Wu, A. T. H., & Huang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656738 · Cited by 52

Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research

Son, B., Lee, W., Kim, H., Shin, H., & Park, H. H. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07077-8 · Cited by 55

Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?

Ameer, S. F., Mohamed, M. Y., Elzubair, Q. A., Sharif, E. A. M., & Ibrahim, W. N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1438040 · Cited by 52

Gene Therapy Strategies Targeting Aging-Related Diseases

Yu, J., Li, T., & Zhu, J. (2022) · Aging and Disease · doi:10.14336/ad.2022.00725 · Cited by 52

New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects

Hu, H., Li, B., Wang, J., Tan, Y., Xu, M., Xu, W., & Lu, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114778 · Cited by 58

Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment

Hage, A., & Dormond, O. (2021) · Cancers · doi:10.3390/cancers13061359 · Cited by 51

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas

Murugan, A. K., & Alzahrani, A. (2022) · British Journal of Biomedical Science · doi:10.3389/bjbs.2021.10208 · Cited by 45

Emerging role and therapeutic implication of mTOR signalling in intervertebral disc degeneration

Chen, H., Zhou, J., Zhang, G., Luo, Z., Li, L., & Kang, X. (2022) · Cell Proliferation · doi:10.1111/cpr.13338 · Cited by 45

Special issue: PI3K/Akt signaling in human cancer

Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.022 · Cited by 45

A natural product solution to aging and aging-associated diseases

Yang, C., Zhang, W., Dong, X., Fu, C., Yuan, J., Xu, M., Liang, Z. C., Qiu, C., & Xu, C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107673 · Cited by 43

The dual roles of A20 in cancer

Shi, Y., Wang, X., Wang, J., Wang, X., Zhou, H., & Zhang, L. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.017 · Cited by 46

Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy

Huan, J., Grivas, P. D., Birch, J., & Hansel, D. E. (2022) · Cancers · doi:10.3390/cancers14061555 · Cited by 45

Exploring the mTOR Signalling Pathway and Its Inhibitory Scope in Cancer

Mir, S. A., Dar, A., Alshehri, S. A., Wahab, S., Hamid, L., Almoyad, M. A. A., Ali, T., & Bader, G. N. (2023) · Pharmaceuticals · doi:10.3390/ph16071004 · Cited by 45

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)

Huang, X., You, L., Nepovimová, E., Psotka, M., Maliňák, D., Valko, M., Sivák, L., Korábečný, J., Heger, Z., Adam, V., et al. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2237209 · Cited by 44

Functional Amino Acids and Autophagy: Diverse Signal Transduction and Application

Liu, C., Ji, L., Hu, J., Zhao, Y., Johnston, L. J., Zhang, X., & Ma, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111427 · Cited by 44

mTOR inhibitors in targeting autophagy and autophagy-associated signaling for cancer cell death and therapy

Senapati, P. K., Mahapatra, K. K., Singh, A., & Bhutia, S. K. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189342 · Cited by 44

Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation

Pelizzaro, F., Gambato, M., Gringeri, E., Vitale, A., Cillo, U., Farinati, F., Burra, P., & Russo, F. P. (2021) · Cancers · doi:10.3390/cancers13194882 · Cited by 42

Delivery of Rapamycin by Liposomes Synergistically Enhances the Chemotherapy Effect of 5-Fluorouracil on Colorectal Cancer

Chen, Y., Zhu, W., Lin, C.-Y., Yuan, Z., Li, Z.-H., & Yan, P. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s270939 · Cited by 42

Erianin: A phytoestrogen with therapeutic potential

Li, G., Zhang, H., Lai, H., Liang, G., Huang, J., Zhao, F., Xie, X., & Peng, C. Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1197056 · Cited by 39

The role of the mTOR pathway in breast cancer stem cells (BCSCs): mechanisms and therapeutic potentials

Zhang, C., Xu, S., Yin, C., Hu, S., & Liu, P. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04218-4 · Cited by 39

circEXOC6B interacting with RRAGB, an mTORC1 activator, inhibits the progression of colorectal cancer by antagonizing the HIF1A-RRAGB-mTORC1 positive feedback loop

Li, X., Wang, J., Lin, W., Yuan, Q., Lu, Y., Wang, H., Chen, L., Chen, L., Dai, P., Long, H., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01600-1 · Cited by 38

mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/+LSL-KrasG12D/+Pdx-1-Cre murine models

Qiu, J., Feng, M., Yang, G., Cao, Z., Liu, Y., You, L., & Zhang, T. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216020 · Cited by 38

The promising therapeutic effects of metformin on metabolic reprogramming of cancer-associated fibroblasts in solid tumors

Mostafavi, S., Zalpoor, H., & Hassan, Z. M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00356-2 · Cited by 41

Cardiovascular Risk After SARS-CoV-2 Infection Is Mediated by IL18/IL18R1/HIF-1 Signaling Pathway Axis

Zhang, L., Li, M., Wang, Z., Sun, P., Wei, S., Zhang, C., Wu, H., & Bai, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.780804 · Cited by 35

mTOR Signaling Components in Tumor Mechanobiology

Gargalionis, A. N., Papavassiliou, K. A., Basdra, E. K., & Papavassiliou, A. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031825 · Cited by 36

The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma

Zhang, P., Ono, A., Fujii, Y., Hayes, C. N., Tamura, Y., Miura, R., Shirane, Y., Nakahara, H., Yamauchi, M., Uchikawa, S., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34247 · Cited by 35

Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma

Guenzle, J., Akasaka, H., Joechle, K., Reichardt, W., Venkatasamy, A., Hoeppner, J., Hellerbrand, C., Fichtner‐Feigl, S., & Lang, S. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010030 · Cited by 34

Carbonic anhydrase IX-targeted H-APBC nanosystem combined with phototherapy facilitates the efficacy of PI3K/mTOR inhibitor and resists HIF-1α-dependent tumor hypoxia adaptation

Liu, J., Hu, X., Feng, L., Lin, Y., Liang, S., Zhu, Z., Shi, S., & Dong, C. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01394-w · Cited by 38

The potential value of cuprotosis (copper-induced cell death) in the therapy of clear cell renal cell carcinoma

Qi, X. (2022) · American Journal of Cancer Research · doi:10.62347/etjh6697 · Cited by 34

LncRNA‐MALAT1 Regulates Cancer Glucose Metabolism in Prostate Cancer via MYBL2/mTOR Axis

Mu, X., Shen, Z., Lin, Y., Xiao, J., Xia, K., Xu, C., Chen, B., Shi, R., Zhu, A.-Y., Sun, X., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8693259 · Cited by 33

MiR-451a promotes cell growth, migration and EMT in osteosarcoma by regulating YTHDC1-mediated m6A methylation to activate the AKT/mTOR signaling pathway

Cao, D., Ge, S., & Li, M. (2022) · Journal of bone oncology · doi:10.1016/j.jbo.2022.100412 · Cited by 32

Long Non-Coding RNAs (lncRNAs) as Regulators of the PI3K/AKT/mTOR Pathway in Gastric Carcinoma

Riquelme, I., Pérez-Moreno, P., Mora‐Lagos, B., Ili, C., Brebi, P., & Roa, J. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076294 · Cited by 32

Growth or death? Control of cell destiny by mTOR and autophagy pathways

Khalil, M. I. M., Ali, M. M., Holail, J., & Houssein, M. (2023) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2023.10.002 · Cited by 32

GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells

Zhang, X., Zhang, L., Wang, B., Zhang, X., Gu, L., Guo, K., Zhang, X., & Zhou, Z. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.14.37 · Cited by 32

Exosomes and their roles in the chemoresistance of pancreatic cancer

Pan, Y., Tang, H., Li, Q., Chen, G., & Li, D. (2022) · Cancer Medicine · doi:10.1002/cam4.4830 · Cited by 30

mTOR signaling: A pivotal player in Treg cell dysfunction in systemic lupus erythematosus

Zhao, X., Wang, S., Wang, S., Xie, J., & Cui, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109153 · Cited by 36

NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets

Indini, A., Fiorilla, I., Ponzone, L., Calautti, E., & Audrito, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179985 · Cited by 31

Adipocytic Glutamine Synthetase Upregulation via Altered Histone Methylation Promotes 5FU Chemoresistance in Peritoneal Carcinomatosis of Colorectal Cancer

Zhang, X., Li, Q., Du, A., Li, Y., Shi, Q., Chen, Y., Zhao, Y., Wang, B., & Pan, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.748730 · Cited by 28

Xanthatin suppresses proliferation and tumorigenicity of glioma cells through autophagy inhibition via activation of the PI3K‐Akt–mTOR pathway

Chen, H., Zhu, T., Huang, X., Xu, W.-S., Di, Z., Ma, Y., Xue, M., Bi, S., Shen, Y., Yu, Y., et al. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1041 · Cited by 27

Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects

Cheng, D., Ge, K., Yao, X., Wang, B., Chen, R., Zhao, W., Fang, C., & Ji, M. Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1209947 · Cited by 28

ZEA-induced autophagy in TM4 cells was mediated by the release of Ca2+ activates CaMKKβ-AMPK signaling pathway in the endoplasmic reticulum

Feng, N., Wang, B., Cai, P., Zheng, W., Zou, H., Gu, J., Yuan, Y., Liu, X., Liu, Z., & Bian, J. (2020) · Toxicology Letters · doi:10.1016/j.toxlet.2020.01.010 · Cited by 28

Protective Effects of Propofol on Rats with Cerebral Ischemia–Reperfusion Injury Via the PI3K/Akt Pathway

Chen, Y., & Li, Z. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01703-8 · Cited by 29

Impact of inflammation and immunotherapy in renal cell carcinoma (Review)

Shi, J., Wang, K., Xiong, Z., Yuan, C., Wang, C., Cao, Q., Huang, Y., Meng, X., Xie, K., Cheng, Z., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.12135 · Cited by 28

Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways

Lan, J., Huang, J., Tao, X., Gao, Y., Zhang, L., Huang, W., Luo, J., Liu, C., Deng, Y., Liu, L., et al. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17278 · Cited by 27

Molecular mechanisms in regulation of autophagy and apoptosis in view of epigenetic regulation of genes and involvement of liquid-liquid phase separation

Chakraborty, S., Nandi, P., Mishra, J., Niharika, N., Roy, A., Manna, S., Baral, T., Mishra, P., Mishra, P. K., & Patra, S. K. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216779 · Cited by 30

MUC3A promotes the progression of colorectal cancer through the PI3K/Akt/mTOR pathway

Su, W., Feng, B., Hu, L., Guo, X., & Yu, M. (2022) · BMC Cancer · doi:10.1186/s12885-022-09709-8 · Cited by 27

Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling

Luo, Y., Liu, X., Fang, L., Yu, H., Zhang, Y., Chen, M., Zhang, L.-D., & Xie, C. (2022) · Theranostics · doi:10.7150/thno.76873 · Cited by 28

ALYREF recruits ELAVL1 to promote colorectal tumorigenesis via facilitating RNA m5C recognition and nuclear export

Zhong, L., Wu, J., Zhou, B., Kang, J., Wang, X., Ye, F., & Lin, X. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00737-0 · Cited by 28

G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway

Li, R., Ke, M., Mingming, Q., Han, Z., Cao, Y., Deng, Z., Qian, J., Yang, Y., & Gu, C. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00326-6 · Cited by 26

mTOR (Mammalian Target of Rapamycin): Hitting the Bull’s Eye for Enhancing Neurogenesis After Cerebral Ischemia?

Gao, J., Yao, M., Chang, D., & Liu, J. (2022) · Stroke · doi:10.1161/strokeaha.122.040376 · Cited by 26

The roles and mechanisms of circular RNAs related to mTOR in cancers

Cao, C., Wang, Y., Wu, X., Li, Z., Guo, J., & Sun, W. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24783 · Cited by 26

Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis

Xie, J., Shen, K., Jones, A. T., Yang, J., Tee, A. R., Shen, M. H., Yu, M., Irani, S., Wong, D., Merrett, J. E., et al. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03491-1 · Cited by 27

Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer

Sapir, T., Shifteh, D., Pahmer, M., Goel, S., & Maitra, R. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0745 · Cited by 25

Targeting mTOR for cancer therapy

Hua, H. M., Kong, Q., Zhang, H., Wang, J., Luo, T. L., & Jiang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0754-1 · Cited by 929

Current treatment strategies for inhibiting mTOR in cancer

Chiarini, F., Evangelisti, C., McCubrey, J. A., & Martelli, A. M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.004 · Cited by 279

Tests génétiques, le cadre législatif en France et en Europe

Delpech, M. (2005) · Annales d Endocrinologie · doi:10.1016/s0003-4266(05)81765-2

Polymorphisme – 493 G/T du gène de la microsomal triglycéride transfer protein et infarctus du myocarde chez une population tunisienne

Jemaa, R., Abid, M., Kallel, A., Chabrak, S., Mn, K., Elasmi, M., Feki, M., & Kaabachi, N. (2005) · Annales d Endocrinologie · doi:10.1016/s0003-4266(05)81788-3

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short Overview

Basnet, R., Basnet, B. B., Gupta, R., Basnet, T. B., Khadka, S., & Alam, M. S. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230331081959 · Cited by 11